Advanced searches left 3/3

Temsirolimus - Europe PMC

Summarized by Plex Scholar
Last Updated: 05 July 2022

* If you want to update the article please login/register

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.

Patients with relapsed and refractory lymphomas were enrolled in a multicenter phase I/III study that compared TEM/LEN and TEM/LEN in patients with relapsed and refractory lymphomas. There were 18 patients in the phase I dose-finding study, and TEM 25 mg weekly and LEN 20 mg daily were the recommended phase II dose for day 1 and day 21. The majority of patients were accepted in the phase II cohort, which included diffuse large B-cell lymphoma, follicular lymphoma, and an exploratory cohort of other lymphoma histologies with classical Hodgkin lymphoma. Patients with cHL were highly supervised with a median of four prior treatments and one-third with relapse after autologous stem cell transplantation; patients with cHL had a median of six prior therapies. Following TEM/LEN therapy, eight cHL patients progressed to allogeneic transplantation.

Source link: https://europepmc.org/article/MED/34320785

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions